Aurinia Announces 2023 Annual General Meeting Results
17 Maio 2023 - 1:14PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the
“Company”) today announced voting results for its annual general
meeting (the “Meeting”) of shareholders held on May 17, 2023.
Shareholders re-elected six of eight incumbent directors to the
Board of Directors (the “Board”). Two directors, George Milne and
Joseph (“Jay”) Hagan, while elected under applicable corporate law,
received less than majority support and have submitted their
resignations for consideration by the Board, pursuant to the
Company’s Majority Voting Policy. In accordance with the policy,
the Board intends to act expeditiously in respect to the submitted
resignations to ensure an orderly transition.
In addition, the Company’s re-appointment of
PricewaterhouseCoopers, LLP as its independent registered public
accounting firm received majority support, while the proposed
amendment to the equity incentive plan was not approved. The
existing equity incentive plan continues unaffected, without
amendment. The non-binding advisory vote on executive compensation
did not receive majority support.
“We respect the outcome of this year’s vote and the opinions of
all of our shareholders. We recognize there is significant work
ahead of us. We look forward to continuing our dialog with
investors and building shareholder value, in the best interests of
the Company,” said Hector MacKay-Dunn, Chair of Aurinia’s
Governance & Nomination Committee.
“We acknowledge investor concerns regarding our executive
compensation. We have had extensive outreach and discussions about
our executive renumeration program in recent years. While we have
made changes to reflect their feedback, such as adopting a share
ownership policy for our directors and executives, instituting a
claw back policy for our executives, and incorporating detailed
performance-based metrics, we will continue to evolve our program
and will share any action steps taken in response to shareholder
input”, MacKay-Dunn concluded.
Peter Greenleaf, Director, President and CEO, stated, “We remain
focused on executing on our strategy and building on Aurinia’s
significant momentum. We appreciate George and Jay’s contributions
in positioning us for our next stage of growth, and we look forward
to working with our shareholders and other stakeholders to advance
Aurinia’s mission of transforming people’s lives by delivering
therapeutics that change the course of rare, autoimmune and kidney
related diseases.”
Voting results on all matters voted on at the Meeting will be
filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations with a high unmet medical need that are impacted by
autoimmune, kidney and rare diseases. In January 2021, the Company
introduced LUPKYNIS® (voclosporin), the first FDA-approved oral
therapy dedicated to the treatment of adult patients with active
lupus nephritis. The Company’s head office is in Edmonton, Alberta,
its U.S. commercial office is in Rockville, Maryland. The Company
focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230517005675/en/
Investor/Media Contact: Aurinia@westwicke.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024